Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 177-182

  Perez Ruiz, Fernando ^a,b   Martínez Indart, Lorea ^a   Carmona, Loreto ^c   Herrero Beites, Ana Maria ^b,d   Pijoan, Jose Ignacio ^a   Krishnan, Eswar ^e  

^a HOSPITAL DE CRUCES   (Spain)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^d Division of Physical Medicine Hospital de Górliz Astondo Ibiltoki   (Spain)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOOP DIURETIC AGENT; URATE;

ADULT; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; FOLLOW UP; GOUT; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; TOPHACEOUS GOUT; URIC ACID BLOOD LEVEL;

CARDIOVASCULAR DISEASE; GOUT; OUTCOMES RESEARCH;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GOUT; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; URIC ACID; YOUNG ADULT;

EID: 84889682611     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202421     Document Type: Article

References (36)

1. Krishnan E, Backer JF, Furst DE, et al. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96. (Pubitemid 44208638)
2. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894-900. (Pubitemid 47300913)
3. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012;2:e000282
4. Kuo CF, Yu KH, See LC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 2013;52: 111-7.
5. Teng GG, Ang LW, Saag KG, et al. Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 2012;7:924-8.
6. Krishnan E, Pandya BJ, Lingala B, et al. Hyperuricaemia and untreated gout are poor prognostic markers among those with a recent acute myocardial infarction. Arthritis Res Ther 2012;14:R10.
7. Krishnan E, Pandya BJ, Chung L, et al. Hyperuricaemia and the risk for subclinical coronary atherosclerosis - data from a prospective observational cohort study. Arthritis Res Ther 2011;131:R:66.
8. Cukurova S, Pamuk ÖN, Ünlü E, et al. Subclinical atherosclerosis in gouty arthritis patients: a comparative study. Rheumatol Int 2012;32:1769-73.
9. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatology 2010;49:1229-38.
10. Lioté F, Ea HK. Gout: update on some pathogenic and clinical aspects. Rheum Dis Clin North Am 2006;32:295-311. (Pubitemid 44250815)
11. Neogi T, George J, Rekhraj S, et al. Are either or both hyperuricaemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal. Arthritis Rheum 2012;64:327-38.
12. Perez-Ruiz F, Lopez J Ruiz, Beites A Herrero. Influence of the natural history of disease on a previous diagnosis in patients with gout. Reumatol Clin 2009;5:248-51.
13. Baker JF, Schumacher HR, Krishnan E. Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology 2007;58:450-7. (Pubitemid 47301052)
14. Krishnan E, Svendsen K, Neaton JD, et al. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104-10. (Pubitemid 351749228)
15. Kim SY, Guevara JP, Kim KM, et al. Hyperuricaemia and coronary heart disease: a systematic review and meta-analysis. Arthitis Rheum 2010;62:170-80.
16. Wheeler JG, Juzwishin KD, Eiriksdottir G, et al. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2005;2:e76.
17. Strazzullo P, Puig JG. Uric acid and cardiovascular risk: Is the devil always so bad? Nutr Metab Cardiovasc Dis 2007;17:409-14.
18. Chou CT, Lai JS. The epidemiology of hyperuricaemia and goit in Taiwan aborigenes. Br J Rheumatol 1998;37:258-62.
19. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology 2009;48:804-6.
20. Tavil Y, Kaya MG, Oktar SÖ, et al. Uric acid level and its association with carotid intima-media thickness in patients with hypertension. Atherosclerosis 2008;197:159-63. (Pubitemid 351273235)
21. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricaemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421-6.
22. Sarawate AC, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares. Analysis from managed care data. J Clin Rheumatol 2006;12:61-5. (Pubitemid 44309598)
23. Riedel AA, Nelson M, Joseph-Ridge N, et al. Compliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claims. J Rheumatol 2006;31:1575-81.
24. Yü TF, Gutman AB. Principles of current management of primary gout. Am J Med Sci 1967;254:893-907.
25. Puig JG, de ME, Castillo MC, et al. Asymptomatic hyperuricaemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008;27:592-5.
26. Pascual E. Persistence of monosodium urate crystals and low-grade inflammation in synovial fluid of patients with untreated gout. Arthritis Rheum 1991;34:141-5.
27. Meek IL, Picavet HS, Vonkeman HE, et al. Increased cardiovascular risk factors in different rheumatic diseases compared with the general population. Rheumatology (Oxford) 2013;52:210-6.
28. Puig JG, Michán AD, Jimenez ML, et al. Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 1991;151:726-32.
29. Scott JT, Holloway VP, Glass HI, et al. Studies on uric acid pool size and turover rate. Ann Rheum Dis 1969;28:366-73.
30. Aviña-Zubieta JA, Choi HK, Safavi MS, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
31. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout Part II. Management. Report of a Task Force of the EULAR Standing Committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24. (Pubitemid 44620440)
32. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007;34:1888-93. (Pubitemid 350067651)
33. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60. (Pubitemid 34856121)
34. Wright SA, Filippucci E, McVeigh C, et al. High resolution ultrasonography of the 1st metatarsal phalangeal joint in gout: a controlled study. Ann Rheum Dis 2006;66:859-64. (Pubitemid 46999784)
35. Chen SY, Chen CL, Shen ML. Severity of gouty arthritis is associated with Q-wave myocardial infarction: a large-scale, cross-sectional study. Clin Rheumatol 2007;26:308-13.
36. Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An audit of the variability of diagnosis and management of gout in the rheumatology setting: the gout evaluation and management study. J Clin Rheumatol 2011;17:349-55